Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101250 | 0.82 | CHEK1 (0.43) | PARP1MEN1CYP3A4MAPTCYP2C9 | |
| SCHEMBL7915346 | 0.81 | GSK3B (0.42) | PARP1CASP7NPSR1MEN1RGS12 | |
| SCHEMBL339346 | 0.80 | GAA (0.41) | PARP1CASP7NPSR1MEN1RGS12 | |
| SCHEMBL1654813 | 0.80 | ALOX5 (0.51) | PARP1MEN1RECQLKMT2ATDP1 | |
| SCHEMBL7767469 | 0.78 | MEN1 (0.50) | MEN1MAPTRECQLKMT2ATDP1 | |
| SCHEMBL3079295 | 0.76 | CES1 (0.63) | PARP1CASP7NPSR1MEN1RGS12 | |
| SCHEMBL31241414 | 0.76 | CES1 (0.63) | PARP1CASP7NPSR1MEN1RGS12 | |
| SCHEMBL6101809 | 0.74 | NQO1 (0.58) | PARP1MEN1MAPTKMT2ACHEK1 | |
| SCHEMBL338831 | 0.74 | PARP1 (0.51) | PARP1CASP7NPSR1MEN1RGS12 | |
| SCHEMBL11310333 | 0.72 | ERN1 (0.41) | PARP1CASP7MEN1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | claimed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | claimed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | claimed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | claimed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | claimed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-7291629-B2 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-11-06 | — | — | US | disclosed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | disclosed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | PARP1 3976/4885CASP7 155/4885NPSR1 45/4885 |
| US-20050250807-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | PARP1 4027/4885CASP7 86/4885NPSR1 49/4885 |
| US-20020169182-A1 | Neurotrophin antagonist compositions | NTRK2, NGF, BDNF | PARP1 4325/4885CASP7 467/4885NPSR1 168/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | PARP1 4114/4885CASP7 90/4885NPSR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.